These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 30168272)
1. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study. Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272 [TBL] [Abstract][Full Text] [Related]
2. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453 [TBL] [Abstract][Full Text] [Related]
3. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M; Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice. Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281 [TBL] [Abstract][Full Text] [Related]
5. Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission. Terslev L; Brahe CH; Østergaard M; Fana V; Ammitzbøll-Danielsen M; Møller T; Krabbe S; Hetland ML; Døhn UM Arthritis Res Ther; 2021 Feb; 23(1):48. PubMed ID: 33522948 [TBL] [Abstract][Full Text] [Related]
6. Musculoskeletal ultrasound as a biomarker of remission - results from a one-year prospective study in patients with rheumatoid arthritis. Sapundzhieva T; Karalilova R; Batalov A Med Ultrason; 2018 Dec; 20(4):453-460. PubMed ID: 30534652 [TBL] [Abstract][Full Text] [Related]
7. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H; J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689 [TBL] [Abstract][Full Text] [Related]
8. Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial. Yasuda S; Ohmura K; Kanazawa H; Kurita T; Kon Y; Ishii T; Fujieda Y; Jodo S; Tanimura K; Minami M; Izumiyama T; Matsumoto T; Amasaki Y; Suzuki Y; Kasahara H; Yamauchi N; Kato M; Kamishima T; Tsutsumi A; Takemori H; Koike T; Atsumi T Mod Rheumatol; 2017 Nov; 27(6):930-937. PubMed ID: 28150514 [TBL] [Abstract][Full Text] [Related]
9. Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission? Janta I; Valor L; De la Torre I; Martínez-Estupiñán L; Nieto JC; Ovalles-Bonilla JG; Martínez-Barrio J; Bello N; Hinojosa M; Montoro M; González CM; López-Longo J; Monteagudo I; Carreño L; Naredo E Rheumatol Int; 2016 Mar; 36(3):387-96. PubMed ID: 26712373 [TBL] [Abstract][Full Text] [Related]
10. Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA): A multicenter RA ultrasound prospective cohort in Japan. Kawashiri SY; Endo Y; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aramaki T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Nagano S; Tada Y; Kawakami A Medicine (Baltimore); 2021 Jul; 100(28):e26592. PubMed ID: 34260539 [TBL] [Abstract][Full Text] [Related]
11. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. Geng Y; Han J; Deng X; Zhang Z Clin Rheumatol; 2014 Aug; 33(8):1061-6. PubMed ID: 24777468 [TBL] [Abstract][Full Text] [Related]
12. Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. Horton SC; Tan AL; Freeston JE; Wakefield RJ; Buch MH; Emery P Rheumatology (Oxford); 2016 Jul; 55(7):1177-87. PubMed ID: 26998766 [TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study. Suzuki M; Takahashi N; Kida D; Hirano Y; Kato T; Yabe Y; Oguchi T; Fujibayashi T; Hayashi M; Asai S; Ishiguro N; Kojima T Int J Rheum Dis; 2019 Dec; 22(12):2199-2205. PubMed ID: 31647174 [TBL] [Abstract][Full Text] [Related]
14. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332 [TBL] [Abstract][Full Text] [Related]
15. Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. Kojima T; Takahashi N; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Shioura T; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Terabe K; Takemoto T; Asai N; Ishiguro N Clin Rheumatol; 2016 Jan; 35(1):219-25. PubMed ID: 26631102 [TBL] [Abstract][Full Text] [Related]
16. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795 [TBL] [Abstract][Full Text] [Related]
17. Relation of Doppler ultrasound synovitis versus clinical synovitis with changes in native complement component levels in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs. Montoro Alvarez M; Chong OY; Janta I; González C; López-Longo J; Monteagudo I; Valor L; Garrido J; Lau IS; Rosman A; Naredo E; Carreño L Clin Exp Rheumatol; 2015; 33(2):141-5. PubMed ID: 25665178 [TBL] [Abstract][Full Text] [Related]
18. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy? Marks JL; Holroyd CR; Dimitrov BD; Armstrong RD; Calogeras A; Cooper C; Davidson BK; Dennison EM; Harvey NC; Edwards CJ Arthritis Care Res (Hoboken); 2015 May; 67(6):746-53. PubMed ID: 25605045 [TBL] [Abstract][Full Text] [Related]
19. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors. Terslev L; Ostergaard M; Georgiadis S; Brahe CH; Ellegaard K; Dohn UM; Fana V; Møller T; Juul L; Huynh TK; Krabbe S; Ornbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Hetland ML RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549857 [TBL] [Abstract][Full Text] [Related]
20. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]